If you have been reading about c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-14. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
In a December 2022 editorial published just before being elected US House speaker, Kevin McCarthy wrote that "China and the US are locked in a cold war". The op-ed also announced the creation of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party. In early 2023, Jorge Heine, former Chilean ambassador to China and professor of international relations at Boston University, said the looming new Cold War between the US and China has become apparent to "a growing consensus", and described the new Cold War as "more alike than [it is] different" from the one fought between the US and Soviet Union, and saying the presence of "ideological-military overtones is now widely accepted". After the 2023 Chinese balloon incident, Evan Osnos wrote for The New Yorker "The blocs in this new cold war are hardening." Shortly after the Russian invasion of Ukraine, Germany had "announced a 'turning point'" in its relationship with Russia. The 2022 Madrid NATO summit hosted leaders from South Korea, Australia, Japan, and New Zealand, who all "voiced unprecedented concern about China's ambitions". The Biden administration strengthened the U.S.'s military ties and activities with Australia, Japan, India, and the Philippines, to "bolster its ability to defend Taiwan". In the October 2024 article for the TomDispatch blog, a history professor Alfred W. McCoy wrote that, despite rising renewed tensions between China and the US, the Asia-Pacific allies of the US would be likely losers.
=== Jasmine Trussell Braverman === Jasmine Trussell (Joy Bryant) is a dancer, the mother of Crosby's son Jabbar, and Crosby's eventual wife. After several attempts to contact Crosby, she kept Jabbar a secret from him until Jabbar was five years old, and wanted to meet his dad. She also falsely tells her own family that Crosby had abandoned her and Jabbar for that time period, because her own father disappeared on her family when she was only four years old. She is very close with her mother, Renee, and her brother, Sekou. She breaks up with Crosby when he cheats on her with Gaby, behavioural aide to his nephew, Max. In the season two finale, it appeared that she and Crosby might reconcile, however, they did not. She subsequently dates her son's pediatrician, Dr. Joe. She appears jealous when Crosby is in a relationship with a cellist from the Luncheonette. In the season three finale, she marries Crosby. By the end of season four, Jasmine reveals that she is pregnant with her and Crosby's second child, a daughter named Aida, who is born at the start of season five. In the series finale she is shown pregnant with another child.
=== Morphology === Vernix is composed of mobile corneocytes embedded in an amorphous lipid matrix. Precise biological mechanisms leading to its formation are poorly understood. The cells are polygonal or ovoid in shape, malleable, and lack nuclei; typical thickness is 1-2 μm. Nuclear ghosts are frequently observed and Acid Phosphatase Activity is nonuniform. Keratin filaments build a scaffold like structure which form a water-storage area. As opposed to stratum corneum, the vernix corneocytes lack desmosomal attachment and the lipid layer is more disordered.
Sources: en.wikipedia.org
organizing international conferences and workshops in mass spectrometry improving mass spectrometry education standardizing terminology in the field aiding in the dissemination of mass spectrometry through publications
== Function == This gene encodes a protein that is a transmembrane receptor for growth hormone. Binding of growth hormone to the receptor leads to reorientation of a pre-assembled receptor dimer dimerization (the receptor may however also exist as monomers on the cell surface ) and the activation of an intra- and intercellular signal transduction pathway leading to growth. A common alternate allele of this gene, called GHRd3, lacks exon three and has been well characterized. Mutations in this gene have been associated with Laron syndrome, also known as the growth hormone insensitivity syndrome (GHIS), a disorder characterized by short stature (proportional dwarfism). Other splice variants, including one encoding a soluble form of the protein (GHRtr), have been observed but have not been thoroughly characterized. Laron mice (that is mice genetically engineered to carry defective Ghr), have a dramatic reduction in body mass (only reaching 50% of the weight of normal siblings), and also show a ~40% increase in lifespan.
clinical assessment and monitoring interventions assessments and prevention of harm To streamline management, there are 5 phases of therapy from the time of recognition of the condition to resolution:
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.